Update on colchicine, 2017

EULAR recommendations for the management of familial Mediterranean fever: Table 1

(2016) Seza Ozen et al.   ANNALS OF THE RHEUMATIC DISEASES

2016 updated EULAR evidence-based recommendations for the management of gout

(2016) P Richette et al.   ANNALS OF THE RHEUMATIC DISEASES

Colchicine toxicity in renal patients – Are we paying attention?

(2016) Samar Medani et al.   CLINICAL NEPHROLOGY

GOSPEL 2 – Colchicine for the treatment of gout flares in France – a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age

(2016) Tristan Pascart et al.   JOINT BONE SPINE

Colchicine: Old and New

(2015) Anastasia Slobodnick et al.   AMERICAN JOURNAL OF MEDICINE

Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims

(2015) Daniel H Solomon et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-Inflammatory Treatment With Colchicine in Acute Myocardial InfarctionClinical Perspective

(2015) Spyridon Deftereos et al.   CIRCULATION

Effect of Colchicine on Platelet-Platelet and Platelet-Leukocyte Interactions: a Pilot Study in Healthy Subjects

(2015) Binita Shah et al.   INFLAMMATION

Colchicine—Update on mechanisms of action and therapeutic uses

(2015) Ying Ying Leung et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Gout Is a Chronic Inflammatory Disease in Which High Levels of Interleukin-8 (CXCL8), Myeloid-Related Protein 8/Myeloid-Related Protein 14 Complex, and an Altered Proteome Are Associated With Diabetes Mellitus and Cardiovascular Disease

(2015) Laura B. E. Kienhorst et al.   Arthritis & Rheumatology

Effect of Steady-State Atorvastatin on the Pharmacokinetics of a Single Dose of Colchicine in Healthy Adults Under Fasted Conditions

(2014) Matthew W. Davis et al.   CLINICAL DRUG INVESTIGATION

Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease

(2014) Suman Wason et al.   CLINICAL DRUG INVESTIGATION

Mechanism of Action of Colchicine in the Treatment of Gout

(2014) Nicola Dalbeth et al.   CLINICAL THERAPEUTICS

Pharmacokinetics considerations for gout treatments

(2014) Pascal Richette et al.   Expert Opinion on Drug Metabolism & Toxicology

Colchicine — a short history of an ancient drug

(2014) Nitesh Nerlekar et al.   MEDICAL JOURNAL OF AUSTRALIA

The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia–reperfusion injury

(2013) Øystein Sandanger et al.   CARDIOVASCULAR RESEARCH

Safety profile of anti-gout agents

(2013) Lisa K. Stamp   CURRENT OPINION IN RHEUMATOLOGY

Relationship Between Response to Colchicine Treatment and MDR1 Polymorphism in Familial Mediterranean Fever Patients

(2013) Ahmet Uludag et al.   Genetic Testing and Molecular Biomarkers

Technical Advance: Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments

(2013) Stephan Paschke et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis

(2013) LE Clarson et al.   European Journal of Preventive Cardiology

Are Dosing Adjustments Required for Colchicine in the Elderly Compared with Younger Patients?

(2012) Suman Wason et al.   ADVANCES IN THERAPY

Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout

(2012) DARIA B. CRITTENDEN et al.   JOURNAL OF RHEUMATOLOGY

Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease

(2012) Stefan M. Nidorf et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin

(2012) Danielle H J Oh et al.   MEDICAL JOURNAL OF AUSTRALIA

Genetic Loss of Murine Pyrin, the Familial Mediterranean Fever Protein, Increases Interleukin-1β Levels

(2012) Pamela R. Hesker et al.   PLoS One

Risk of myocardial infarction among patients with gout: a nationwide population-based study

(2012) C.-F. Kuo et al.   RHEUMATOLOGY

2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis

(2012) Dinesh Khanna et al.   ARTHRITIS CARE & RESEARCH

EULAR recommendations for calcium pyrophosphate deposition. Part II: Management

(2011) W. Zhang et al.   ANNALS OF THE RHEUMATIC DISEASES

Inflammasome Activation of Cardiac Fibroblasts Is Essential for Myocardial Ischemia/Reperfusion Injury

(2011) Masanori Kawaguchi et al.   CIRCULATION

Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials

(2011) Robert L. Wortmann et al.   CLINICAL THERAPEUTICS

Unrecognized fatalities related to colchicine in hospitalized patients

(2011) Michael Mullins et al.   CLINICAL TOXICOLOGY

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study

(2010) Robert A. Terkeltaub et al.   ARTHRITIS AND RHEUMATISM

Prevention of Amyloidosis in Familial Mediterranean Fever with Colchicine: A Case-Control Study in Armenia

(2009) Maria K. Sevoyan et al.   MEDICAL PRINCIPLES AND PRACTICE

Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine

(2008) E W Chia et al.   BRITISH JOURNAL OF PHARMACOLOGY

How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases?

(2008) C. Beck et al.   RHEUMATOLOGY INTERNATIONAL

Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation

(2008) George Nuki   Current Rheumatology Reports